# Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 Canonical URL: https://biopharmsignal.com/news/DGX/quest-diagnostics-to-release-second-quarter-financial-results-on-july-23-2026 Ticker: DGX Company: Quest Diagnostics Source: Quest Diagnostics Published: 2026-06-25 13:46 EST Original Source URL: https://newsroom.questdiagnostics.com ## Summary Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026,... ## Article Body Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 , / PRNewswire / -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor . The company suggests participants dial in approximately 10 minutes before the call. A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on July 23, 2026, until midnight Eastern Time on August 6, 2026. Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. About Quest Diagnostics Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors, and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com SOURCE Quest Diagnostics For further information: Dan Haemmerle (Investors): 973-520-2900; Wendy Bost (Media): 973-520-2800 ## Recent Company News - 2026-07-10 13:24 EST — [One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns](https://biopharmsignal.com/news/DGX/one-in-five-american-workers-tested-had-a-positive-hair-drug-test-in-2025-signal-cb4ae34e) — Source: Quest Diagnostics - 2026-07-08 12:52 EST — [Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI](https://biopharmsignal.com/news/DGX/quest-diagnostics-now-the-largest-clinical-reference-lab-to-extend-oncology-test-e734c702) — Source: Quest Diagnostics - 2026-06-29 12:16 EST — [Quest Diagnostics Foundation Commits Nearly $5 Million to Improving Health Outcomes and Food Security in Miami-Dade County, Florida](https://biopharmsignal.com/news/DGX/quest-diagnostics-foundation-commits-nearly-5-million-to-improving-health-outcom-a6539690) — Source: Quest Diagnostics - 2026-06-25 13:46 EST — [Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing](https://biopharmsignal.com/news/DGX/quest-diagnostics-receives-new-york-state-approval-for-haystack-mrdr-broadening-patient-access-to-ctdna-minimal-residual-disease-testing) — Source: Quest Diagnostics - 2026-06-25 13:46 EST — [UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics](https://biopharmsignal.com/news/DGX/uti-causing-bacteria-resistant-to-current-drugs-finds-national-study-by-hackensack-meridian-cdi-and-quest-diagnostics) — Source: Quest Diagnostics ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)